Although further prospective studies using a large cohort is required, PD-L1 expression can potentially serve as a valuable biomarker in identifying those patients with advanced biliary tract cancer who could benefit from pembrolizumab treatment. This evidence concerns the gene CD274 and biliary tract cancer.